65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis

Key Takeaways Explain This Topic AI

Acne vulgaris pathogenesis involves four interconnected targets: follicular hyperkeratinization (microcomedone formation), androgen-mediated sebum overproduction, Cutibacterium acnes proliferation, and perifollicular inflammation; topical retinoids serve as the foundational bedrock of all acne regimens.

Topical antibiotic monotherapy is strictly contraindicated due to rapid bacterial resistance; topical clindamycin must always be co-prescribed with benzoyl peroxide, which exerts bactericidal action via reactive oxygen species with zero documented resistance.

Severe nodulocystic or scarring acne refractory to oral doxycycline (duration strictly capped at 3–4 months) warrants oral isotretinoin (cumulative goal 120–150 mg/kg), which requires strict iPLEDGE REMS compliance, two baseline negative pregnancy tests, monthly pregnancy testing, two forms of contraception, and serial liver/lipid monitoring.

Papulopustular rosacea is definitively distinguished from acne vulgaris by the complete absence of comedones; first-line topical treatments include metronidazole, ivermectin (targeting Demodex folliculorum), and azelaic acid, supplemented with subantimicrobial anti-inflammatory doxycycline (40 mg daily) for moderate-to-severe disease.

Seborrheic dermatitis results from host inflammatory responses to Malassezia yeast in sebum-rich areas; sudden, severe, recalcitrant seborrheic dermatitis is a recognized clinical harbinger of acute HIV infection or Parkinson disease.

Last updated: September 2026

Acne Vulgaris: Pathophysiology & Lesion Morphology

Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit, affecting over 85% of adolescents and young adults, with a growing prevalence among adult females. The disease process is orchestrated by four interconnected, interdependent pathogenic factors that dictate both clinical lesion morphology and pharmacotherapeutic selection.

The Four Interconnected Pathogenic Pillars

Follicular Hyperkeratinization & Microcomedone Formation : Abnormal hyperproliferation and cohesive desquamation of keratinocytes lining the infundibulum of the pilosebaceous follicle lead to retention of stratum corneum cells. This micro-obstruction traps lipids and cellular debris, forming the microscopic precursor of all acne lesions: the microcomedone .

Androgen-Mediated Sebum Overproduction : During adrenarche and puberty, circulating and locally synthesized androgens (primarily dihydrotestosterone [DHT] and dehydroepiandrosterone sulfate [DHEA-S]) bind nuclear androgen receptors on sebocytes. This stimulates marked sebaceous gland hypertrophy and excessive sebum production. Sebum serves as a high-lipid nutrient substrate and alters follicular oxygen tension.

Follicular Proliferation of Cutibacterium acnes : The anaerobically plugged, sebum-rich infundibulum provides an ideal ecological niche for the proliferation of Cutibacterium acnes (formerly Propionibacterium acnes ), an anaerobic, Gram-positive aerotolerant diphtheroid rod that constitutes part of the normal cutaneous microbiome.

Perifollicular Inflammation & Immune Activation : C. acnes hydrolyzes sebum triglycerides into free fatty acids via bacterial lipases. These free fatty acids irritate follicular epithelium. Crucially, C. acnes activates Toll-like receptor 2 (TLR-2) on local monocytes, perifollicular macrophages, and dendritic cells, triggering the transcription factor nuclear factor-kappa B (NF-κB) and the massive release of pro-inflammatory cytokines (interleukin-1α [IL-1α], IL-8, IL-12, and tumor necrosis factor-alpha [TNF-α]). Neutrophils migrate into the follicle, release hydrolytic enzymes, and cause follicular wall thinning and rupture, extruding keratin, lipids, and bacterial antigens into the surrounding dermis and provoking an acute foreign-body inflammatory reaction. THE 4-STEP PATHOGENIC CASCADE OF ACNE VULGARIS

[Excess Androgens] [Altered Desquamation] [Bacterial Overgrowth] [Immune Activation]
│ │ │ │
▼ ▼ ▼ ▼
Sebaceous Gland ───► Follicular Obstruction ───► Cutibacterium acnes ───► TLR-2 / NF-κB Pathway
Hyperplasia & Microcomedone Proliferation Pro-inflammatory Cascade
│ │ │ │
└─────────────────────────┴────────────────────────────┴───────────────────────────┘
│
▼
CLINICAL ACNE LESION SPECTRUM
[Non-inflammatory Comedones ──► Inflammatory Papules/Cysts]
Lesion Morphology & Classification

Clinical lesions are divided into non-inflammatory and inflammatory categories:

Non-Inflammatory Lesions (Comedones) :

Open Comedones ("Blackheads") : Follicular orifices are visibly dilated, plugged with a compact keratin-lipid mass. The dark black coloration is not dirt ; rather, it is caused by the oxidation of melanin and oxidized lipids when exposed to atmospheric air.

Closed Comedones ("Whiteheads") : Tiny, 1- to 2-mm, smooth, flesh-colored to whitish dome-shaped papules without an apparent follicular opening. The keratin plug remains beneath the closed epidermal surface, creating an enclosed anaerobic environment prone to inflammatory rupture.

Inflammatory Lesions :

Papules : Small (<5 mm), erythematous, tender, elevated dome-shaped lesions indicating superficial dermal inflammation around a disrupted follicle.

Pustules : Circumscribed, elevated superficial lesions containing visible whitish-yellow purulent exudate (dead neutrophils and necrotic debris).

Nodules : Deep-seated, firm, painful inflammatory lesions (>5 mm) that extend deep into the dermis and subcutis; indicative of extensive follicular wall rupture.

Cysts : Large, fluctuant, suppurative pseudocysts resulting from coalescent ruptured nodules; carry an extremely high propensity for permanent scarring (ice-pick, rolling, or boxcar atrophic scars, or hypertrophic keloidal scars).

Evidence-Based Stepwise Management (AAD 2024 Guidelines)

The American Academy of Dermatology (AAD) updated clinical practice guidelines stratify management by clinical morphology, severity, and patient-specific factors. Treatment must target as many pathogenic mechanisms simultaneously as possible. EVIDENCE-BASED TREATMENT LADDER FOR ACNE VULGARIS (AAD 2024)

Severity / Type First-Line Medical Regimens Key Counseling & Clinical Pearls

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Mild Comedonal Topical Retinoid Monotherapy Apply at night to dry skin (pea-sized);
Adapalene 0.1% or 0.3% gel/cream normalizes keratinocyte desquamation;
Tretinoin 0.025%–0.1% cream/gel warn about initial "retinoid purge",

Tazarotene 0.05%–0.1% cream/gel erythema, and obligatory photosensitivity.

─────────────────────────────────────────────────────────────────────────────────────────────────────────────

Mild Inflammatory / Topical Retinoid + Benzoyl Peroxide (BPO) 2.5–5% BPO generates reactive oxygen species with

Papulopustular ± Topical Clindamycin 1% solution/gel ZERO bacterial resistance; NEVER PRESCRIBE

(Prefer fixed-dose combination formulations) TOPICAL ANTIBIOTIC MONOTHERAPY.

─────────────────────────────────────────────────────────────────────────────────────────────────────────────
Moderate Inflammatory Topical Retinoid + BPO 2.5–5% + Oral Antibiotic Doxycycline 100 mg daily first-line;
First-line: Doxycycline 100 mg daily HARD CEILING: LIMIT ORAL ANTIBIOTICS

Alternative: Minocycline 50–100 mg BID TO 3–4 MONTHS; pill esophagitis counseling.
Female hormonal therapy adjunct (COC/Spirono) Take with full glass of water, stay upright.

─────────────────────────────────────────────────────────────────────────────────────────────────────────────
Severe Nodulocystic / Oral Isotretinoin Monotherapy Cumulative goal: 120–150 mg/kg;

Scarring / Refractory • 0.5–1.0 mg/kg/day divided BID for 4–6 months Mandatory iPLEDGE REMS program compliance;

(Targets all 4 pathogenic mechanisms!) two forms of contraception; monthly LFTs,

lipid panel, and pregnancy testing.

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Topical Retinoids: The Foundational Bedrock

Topical retinoids bind specific nuclear retinoic acid receptors (RAR-β and RAR-γ), directly normalizing follicular desquamation, accelerating cell turnover, expelling mature comedones, and preventing new microcomedone formation. In addition, retinoids exert indirect anti-inflammatory actions by downregulating TLR-2 expression.

Agents :

Adapalene (0.1% OTC, 0.3% Rx) : Synthetic third-generation naphthoic acid derivative; RAR-β/γ selective. Possesses the highest tolerability profile with the lowest incidence of cutaneous irritation. Photostable, allowing daytime application, and chemically compatible with concomitant benzoyl peroxide.

Tretinoin (0.025%, 0.05%, 0.1%) : All-trans retinoic acid. Highly effective but degraded by light; must be applied strictly at bedtime. Inactivated by direct contact with benzoyl peroxide (must apply at opposite times of day if used uncombined).

Tazarotene (0.05%, 0.1%) : Receptor-selective prodrug; highly potent but exhibits higher rates of localized erythema and peeling. Pregnancy Category X (contraindicated in pregnancy).

Trifarotene (0.005%) : Fourth-generation RAR-γ selective agonist approved for facial and truncal acne.

Patient Counseling Pearl : Apply once daily at bedtime to clean, completely dry skin (waiting 15–20 minutes after washing to reduce stinging). Use a single pea-sized amount distributed across the entire face—not as spot treatment. Anticipate a transient "retinoid dermatitis" (scaling, erythema, dryness) and mild "purging" during the first 2–4 weeks. Daily broad-spectrum SPF ≥30 sunscreen is non-negotiable.

2. Benzoyl Peroxide (BPO): The Resistance-Free Antimicrobial

Benzoyl peroxide is a lipophilic oxidizing agent that readily penetrates the sebum-rich follicular canal. Once inside, it generates reactive oxygen species (ROS / free radicals) , rapidly lysing bacterial cell walls and oxidatively destroying C. acnes proteins.

Zero Resistance : Because its mechanism is physical oxidation rather than target-site receptor binding, there is zero documented bacterial resistance to benzoyl peroxide worldwide , even after decades of continuous clinical use.

Concentration Equivalence : Controlled clinical trials prove that 2.5% or 5% BPO formulations are clinically equivalent in bactericidal efficacy to 10% formulations , but produce markedly less cutaneous irritation, scaling, and contact dermatitis.

Counseling : Warn patients that BPO oxidizes and bleaches colored towels, pillowcases, and clothing.

3. Topical Antibiotics: The Cardinal Prohibition Rule

Topical Clindamycin 1% and Erythromycin 2% inhibit the bacterial 50S ribosomal subunit, reducing C. acnes colony counts and dampening neutrophil chemotaxis.

[!CRITICAL] Never Use Topical Antibiotic Monotherapy Monotherapy with topical clindamycin or erythromycin leads to the rapid selection of macrolide/lincosamide-resistant C. acnes strains within 4 to 8 weeks, rendering therapy completely ineffective and promoting widespread cross-resistance. Topical antibiotics must ALWAYS be combined with benzoyl peroxide (either as fixed-dose combination gels—e.g., clindamycin 1%/BPO 5%—or applied concomitantly).

4. Oral Antibiotics for Moderate-to-Severe Inflammatory Acne

Oral antibiotics are reserved for widespread inflammatory acne (face, chest, back) failing comprehensive topical regimens.

First-Line Agents : Second-generation tetracyclines:

Doxycycline : 100 mg orally once daily (or 50–100 mg BID).

Minocycline : 50–100 mg orally BID (or weight-based extended-release formulation).

Sarecycline : Narrow-spectrum tetracycline targeting C. acnes with low enteric Gram-negative disruption.

Mechanism : Reversibly bind the 30S ribosomal subunit. Crucially, tetracyclines possess powerful intrinsic non-antibiotic anti-inflammatory properties : they inhibit matrix metalloproteinases (MMP-8, MMP-9), suppress neutrophil chemotaxis, and downregulate pro-inflammatory cytokines.

Treatment Duration Cap : The AAD strictly mandates that oral antibiotics be limited to a maximum duration of 3 to 4 months . They must always be co-prescribed with a topical retinoid and benzoyl peroxide. Once inflammatory lesions regress, oral antibiotics should be systematically tapered and discontinued, transitioning the patient to topical retinoid + BPO maintenance therapy.

Adverse Effects & Critical Warnings :

Pill-Induced Esophagitis : Doxycycline produces direct corrosive chemical ulceration if lodged in the esophagus. Patients must take tablets with a full 8-ounce glass of water and remain strictly upright for at least 30 minutes before lying down.

Phototoxicity : Exaggerated sunburn reactions upon UV exposure.

Vestibular Toxicity & Hyperpigmentation : Minocycline can cause dose-dependent vertigo, dizziness, and blue-gray slate pigmentation of skin, sclera, gums, and scars. Rare risks include drug-induced lupus and DRESS syndrome.

Contraindications : Contraindicated in pregnancy and in children under 8 years of age due to permanent tooth discoloration (yellow-gray-brown dentin staining) and reversible suppression of long bone growth.

5. Oral Isotretinoin (Accutane): The Curative Systemic Retinoid

Oral isotretinoin (13-cis-retinoic acid) is the most potent anti-acne medication known, capable of inducing permanent long-term clinical remission.

Targeting All Four Mechanisms : Isotretinoin is the only single agent that simultaneously shuts down all four pathogenic pillars: 1) induces profound sebocyte apoptosis, reducing sebaceous gland size by up to 90% and sebum production by >80%; 2) normalizes infundibular desquamation, eliminating comedogenesis; 3) profoundly deprives C. acnes of its lipid nutrient substrate; and 4) exerts direct anti-inflammatory immunomodulatory actions.

Indications : Severe, scarring nodulocystic acne; moderate inflammatory acne refractory to oral antibiotics; rapidly scarring acne; or severe acne causing profound psychosocial depression/dysmorphia.

Dosing Protocol : Initiated at 0.5 mg/kg/day for month 1, then escalated to 1.0 mg/kg/day divided twice daily with meals containing high dietary fats (absorption is lipid-dependent). Treatment is continued until achieving a cumulative target dose of 120 to 150 mg/kg (typically over 20 to 24 weeks). Achieving this cumulative threshold minimizes the long-term relapse rate.

The iPLEDGE REMS Program :

Isotretinoin is a devastating human teratogen (Embryofetopathy) , causing severe microtia/anotia, micrognathia, cleft palate, conotruncal cardiac defects, hydrocephalus, and intellectual disability in over 30% of exposed fetuses.

The iPLEDGE Mandate : Female patients of childbearing potential must have two negative serum or urine pregnancy tests documented prior to initiation. They must commit to using two independent, effective forms of contraception (or practice continuous, documented complete abstinence) starting 1 month before treatment, throughout the entire treatment course, and for at least 1 full month following complete cessation .

Monthly negative pregnancy tests must be logged into the national registry within a strict 7-day prescription window before each refill is dispensed.

Laboratory Monitoring Protocol :

Baseline: Fasting lipid panel (triglycerides, total cholesterol, HDL), comprehensive metabolic panel (AST, ALT), and complete blood count (CBC).

Follow-up: Repeat fasting lipids and liver transaminases at 1 month, and periodically thereafter until stable. Modest triglyceride elevations (up to 300–400 mg/dL) and mild transaminitis are common; if serum triglycerides exceed 800 mg/dL, isotretinoin must be dose-reduced or halted to prevent acute pancreatitis.

Common Adverse Effects :

Mucocutaneous (100%) : Cheilitis (severe dry, cracked lips is the universal clinical marker of therapeutic compliance), xerosis, epistaxis (nasal vestibulitis), conjunctivitis/dry eyes (contact lens intolerance), brittle nails, and skin fragility.

Musculoskeletal : Arthralgias, back pain, myalgias, elevated serum creatine kinase (CK) following vigorous exercise.

Neuropsychiatric : Active monitoring for depression, suicidal ideation, and mood changes is recommended, although large epidemiological studies have not established a direct causal link.

6. Hormonal Therapies for Adult Females

In adult women with persistent lower-face (jawline and chin) inflammatory papules that flare premenstrually, systemic hormonal manipulation provides superior long-term disease control:

Combined Oral Contraceptives (COCs) : FDA-approved formulations containing ethinyl estradiol paired with low-androgenic progestins (norgestimate, norethindrone) or an anti-androgenic progestin ( drospirenone , a spironolactone analogue). Estrogen increases hepatic synthesis of sex hormone-binding globulin (SHBG), binding free circulating testosterone, while suppressing pituitary LH secretion to dampen ovarian androgen output.

Spironolactone : Aldosterone antagonist that competitively blocks peripheral androgen receptors on sebocytes and inhibits 5-alpha-reductase. Dosed at 50 to 100 mg orally once daily (or divided BID). Reduces sebum excretion by 30–50%. Side effects include menstrual irregularities (addressed by combining with a COC), breast tenderness, lightheadedness, and hyperkalemia. In healthy young women without renal impairment, routine serum potassium monitoring is no longer mandatory, but baseline and periodic checks are prudent in older patients or those taking ACE inhibitors/ARBs. Strict contraindication in pregnancy due to the risk of feminization of a male fetus.

Rosacea: Clinical Subtypes, Diagnosis & Therapeutics

Rosacea is a chronic vascular and neuroinflammatory disorder localized primarily to the convexities of the central face (cheeks, nose, chin, and forehead). It predominantly affects fair-skinned individuals of Celtic or Northern European descent, with peak onset between ages 30 and 50.

Pathophysiology

Rosacea involves neurovascular dysregulation, an exaggerated innate immune response, and microbial trigger factors:

Neurovascular Dysregulation : TRP (transient receptor potential) ion channels on sensory cutaneous nerve endings are hypersensitive, driving intense facial flushing, persistent vasodilation, and burning pain in response to thermal, chemical, or emotional triggers.

Innate Immune Activation : Patients overexpress the antimicrobial peptide cathelicidin (LL-37) , which is cleaved into aberrant vasoactive and pro-inflammatory fragments by elevated stratum corneum kallikrein-5 protease.

Microbiome Overgrowth : Microscopic Demodex folliculorum mites reside in massive excess within the sebaceous follicles, serving as antigenic targets that trigger T-cell and toll-like receptor activation. THE FOUR DISTINCT SUBTYPES OF ROSACEA

Subtype Key Clinical Features First-Line Evidence-Based Management

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Erythematotelan- Persistent centrofacial erythema; recurrent • Strict trigger avoidance (spicy, hot liquids, EtOH)

giectatic (ETR) flushing (> 10 min); prominent telangiectasias; • Daily physical mineral sunscreen (SPF ≥ 30)
burning, stinging; sensitive "reactive" skin. • Topical Brimonidine 0.33% gel / Oxymetazoline 1%

Pulsed Dye Laser (PDL) for fixed telangiectasias.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
2. Papulopustular Confluent erythema with dome-shaped inflammatory • Topical Metronidazole 0.75%–1% gel/cream
papules and tiny pustules across central face; • Topical Ivermectin 1% cream (kills Demodex!)
CARDINAL RULE: COMPLETE ABSENCE OF COMEDONES. • Topical Azelaic Acid 15% gel or foam

Oral Doxycycline 40 mg subantimicrobial daily.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

3. Phymatous Marked sebaceous hyperplasia, follicular dilation, • Early: Oral isotretinoin to shrink sebaceous bulk

dermal edema, and fibrous tissue hypertrophy; • Advanced: Electrosurgical debulking, carbon
RHINOPHYMA: bulbous, lobulated, purplish nose. dioxide (CO2) laser resurfacing, or cold-blade

Occurs almost exclusively in adult males. tangential surgical excision.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

4. Ocular Rosacea Occurs in > 50% of rosacea patients; blepharitis, • Eyelid hygiene (warm compresses, baby shampoo)

conjunctival injection, foreign-body "gritty" • Preservative-free artificial tears
sensation, photophobia, telangiectasia of lid • Topical cyclosporine ophthalmic drops

margin, recurrent chalazia and styes. • Oral Doxycycline 40–100 mg daily for 6–12 weeks.

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

The Cardinal Board Exam Diagnostic Rule

Important

The Presence vs. Absence of Comedones The definitive, high-yield clinical differentiator between acne vulgaris and papulopustular rosacea is that rosacea NEVER features comedones (no blackheads, no whiteheads) . If a patient with central facial papules and pustules has open or closed comedones, the diagnosis is acne vulgaris. If comedones are entirely absent and accompanied by flushing and telangiectasias, the diagnosis is rosacea.

Therapeutic Specifics for Rosacea

Trigger Avoidance & Sun Protection : Elimination of personal triggers: hot beverages, alcohol (especially red wine), spicy capsaicin-containing foods, thermal extremes (saunas, cold wind), and emotional stress. Broad-spectrum physical sunscreens containing micronized zinc oxide or titanium dioxide (SPF ≥30) must be worn daily.

Topical Brimonidine 0.33% Gel & Oxymetazoline 1% Cream : Highly selective alpha-2 and alpha-1 adrenergic receptor agonists , respectively. They cause direct vasoconstriction of dilated cutaneous facial arterioles, providing temporary (8–12 hour) clearing of erythema. Caution : Brimonidine carries a risk of paradoxically severe "rebound flushing" upon wearing off in up to 15% of patients.

Topical Ivermectin 1% Cream : A broad-spectrum anti-parasitic agent that directly eradicates Demodex folliculorum mites while exerting potent anti-inflammatory properties (inhibits NF-κB and lipopolysaccharide-induced inflammatory cytokines). Demonstrates superior clinical clearance over metronidazole 0.75% in head-to-head randomized trials.

Subantimicrobial Anti-inflammatory Dose Doxycycline : Dosed at 40 mg orally once daily (administered as 30 mg immediate-release and 10 mg delayed-release beads). At this low concentration, doxycycline falls below the minimum inhibitory concentration (MIC) required to exert antimicrobial pressure on bacteria, completely avoiding the development of bacterial resistance or vaginal candidiasis. Instead, it powerfully suppresses neutrophil chemotaxis, downregulates cathelicidin LL-37 processing, and inhibits matrix metalloproteinases.

Topical Corticosteroid Contraindication : Fluorinated topical corticosteroids applied to the central face cause temporary improvement followed by catastrophic steroid-induced rosacea , accompanied by epidermal atrophy, profound telangiectasias, and severe pustular rebound eruptions upon withdrawal.

Seborrheic Dermatitis: Clinical Spectrum & Management

Seborrheic dermatitis is an extremely common, chronic, relapsing, superficial inflammatory dermatosis that manifests as greasy, yellowish, micaceous or flaky scales overlying patches of poorly demarcated erythema. It exhibits a predilection for anatomic areas with high concentrations of active sebaceous glands.

Etiopathogenesis: The Malassezia Nexus

The pathogenesis centers on an abnormal host immune response to lipophilic yeasts of the genus Malassezia ( Malassezia globosa and Malassezia restricta ), which reside naturally within sebum-rich hair follicles. Malassezia produces lipases that metabolize sebaceous triglycerides into free fatty acids (oleic and arachidonic acid). These unsaturated fatty acids penetrate the stratum corneum, disrupt the epidermal barrier, and stimulate keratinocyte cytokine release and localized cell-mediated immune inflammation in genetically susceptible individuals. ANATOMIC DISTRIBUTION OF SEBORRHEIC DERMATITIS

Anatomic Site Typical Clinical Findings

Scalp From diffuse, fine, white-to-gray scaling without erythema ("Dandruff" / Pityriasis

capitis) to prominent erythematous plaques with thick, greasy, adherent yellowish crusts.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Central Face Erythema and greasy salmon-pink scaling concentrated along the nasolabial folds,

glabella, medial eyebrows, and hairline borders (corona seborrheica).

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Ears & Canals Retroauricular creases (often fissured and painful), external auditory canals,

and the concha bowl; frequent cause of persistent external otitis.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Trunk & Intertriginous Presternal midline anterior chest (petaloid or circinate greasy patches), interscapular

upper back, axillae, inframammary creases, and umbilicus.

Clinical Variants & High-Yield Systemic Associations

Infantile Seborrheic Dermatitis ("Cradle Cap") :

Arises within the first 2 to 10 weeks of life due to transplacental transfer of maternal androgens stimulating infant sebaceous glands.

Manifests as thick, tenacious, greasy, yellowish-brown crusts and scales over the vertex of the scalp. Lesions may spread to the face, retroauricular folds, and diaper region.

Benign & Self-Limiting : The infant is asymptomatic (does not scratch; non-pruritic). It resolves spontaneously by 6 to 12 months of age.

Management : Reassurance; conservative measures include applying warm mineral oil, baby oil, or petrolatum to the scalp to soften crusts for 20 minutes, followed by gentle mechanical desquamation with a soft-bristled baby toothbrush and washing with a mild baby shampoo. For persistent inflammation, a low-potency topical steroid (hydrocortisone 1% cream) can be applied for several days.

High-Yield Adult Systemic Associations :

[!CRITICAL] Severe Seborrheic Dermatitis as a Marker for HIV & Parkinson Disease

HIV Infection : While mild seborrheic dermatitis occurs in 3–5% of the general population, it occurs in up to 85% of individuals with advanced HIV/AIDS . An explosive, sudden-onset, widespread, fiery-red, treatment-refractory seborrheic dermatitis involving the entire face, neck, and trunk is a classic early clinical harbinger of acute HIV seroconversion or progressing immunosuppression (CD4 count <400/μL). Mandatory Board Rule : Any young or middle-aged adult presenting with sudden, extensive, recalcitrant seborrheic dermatitis must be screened with a fourth-generation HIV-1/2 antigen/antibody immunoassay .

Parkinson Disease & Neurodegenerative Disorders : Seborrheic dermatitis exhibits an extraordinary prevalence in Parkinson disease. Autonomic nervous system dysfunction induces excessive sebum production ("seborrhea") and pooling, coupled with immobility of facial expression (the parkinsonian "masked facies"), creating a fertile environment for Malassezia overgrowth.

Longitudinal Management Strategy

Because seborrheic dermatitis is a chronic condition with an intrinsic genetic and microbial basis, the therapeutic goal is symptom control and maintenance , not permanent eradication.

Scalp Disease (Adult Dandruff & Plaque Disease) :

Medicated Antifungal Shampoos : Ketoconazole 2% shampoo , Selenium sulfide 2.5% , or Zinc pyrithione 1–2% . Patients must lather the shampoo into the scalp and leave it in place for 5 to 10 minutes before rinsing to ensure adequate fungicidal tissue penetration. Use 2 to 3 times weekly.

Topical Corticosteroid Solutions/Foams : For acute intense pruritus and erythema, mid-potency topical corticosteroids (fluocinolone acetonide 0.01% scalp oil or clobetasol 0.05% shampoo used twice weekly) provide rapid symptomatic relief during flares.

Facial and Delicate Skin Folds :

Topical Antifungals : Ketoconazole 2% cream or ciclopirox 0.77% cream applied once to twice daily is the first-line maintenance therapy of choice, directly suppressing Malassezia load without skin-thinning side effects.

Low-Potency Topical Corticosteroids : Hydrocortisone 1% cream or desonide 0.05% cream applied BID for brief bursts (3–5 days) to rapidly extinguish active inflammation.

Steroid-Sparing Topical Calcineurin Inhibitors : Pimecrolimus 1% cream or tacrolimus 0.03%–0.1% ointment are outstanding off-label steroid-sparing maintenance options for sensitive facial, eyelid, and nasolabial folds. They suppress T-cell NFAT transcription without inducing skin atrophy, telangiectasias, or perioral dermatitis.